1. P698: BOSUTINIB DOSE OPTIMIZATION IN THE SECOND-LINE TREATMENT OF ELDERLY CML PATIENTS: EXTENDED 3-YEAR FOLLOW-UP AND FINAL RESULTS OF THE BEST STUDY. (23rd June 2022) Authors: Castagnetti, F.; Bocchia, M.; Abruzzese, E.; Capodanno, I.; Bonifacio, M.; Rege Cambrin, G.; Crugnola, M.; Binotto, G.; Elena, C.; Lucchesi, A.; Bergamaschi, M.; Albano, F.; Luciano, L.; Sorà, F.; Lunghi, F.; Stagno, F.; Cerrano, M.; Iurlo, A.; Scortechini, A. R.; Leonetti Crescenzi, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 593 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P712: ASCIMINIB ITALIAN MANAGED ACCESS PROGRAM: EFFICACY PROFILE IN HEAVILY PRE-TREATED CML PATIENTS. (23rd June 2022) Authors: Breccia, M.; Russo Rossi, A. V.; Martino, B.; Abruzzese, E.; Annunziata, M.; Binotto, G.; Ermacora, A.; Fava, C.; Giaccone, L.; Giai, V.; Nardozza, A. P.; Coco, P.; Gozzini, A.; Levato, L.; Lucchesi, A.; Luciano, L.; Maria Cristina, M.; Rege-Cambrin, G.; Santoro, M.; Scappini, B. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 607 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗